Combined sewer overflows (CSOs) may represent a significant source of pollution, but they are difficult to quantify at a large scale (e.g. regional or national), due to a lack of accessible data. In the present study, we use a large scale, 6-parameter, lumped hydrological model to perform a screening level assessment of different CSO management scenarios for the European Union and United Kingdom, considering prevention and treatment strategies. For each scenario we quantify the potential reduction of CSO volumes and duration, and estimate costs and benefits. A comparison of scenarios shows that treating CSOs before discharge in the receiving water body (e.g. by constructed wetlands) is more cost-effective than preventing CSOs. Among prevention strategies, urban greening has a benefit/cost ratio one order of magnitude higher than grey solutions, due to the several additional benefits it entails. We also estimate that real time control may bring on average a CSO volume reduction of just above 20%. In general, the design of appropriate CSO management strategies requires consideration of context-specific conditions, and is best made in the context of an integrated urban water management plan taking into account factors such as other ongoing initiatives in urban greening, the possibility to disconnect impervious surfaces from combined drainage systems, and the availability of space for grey or nature-based solutions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jenvman.2022.115629DOI Listing

Publication Analysis

Top Keywords

costs benefits
8
combined sewer
8
management strategies
8
large scale
8
cso management
8
urban greening
8
benefits combined
4
sewer overflow
4
management
4
overflow management
4

Similar Publications

Aim: Many studies have revealed the benefits of robotic surgery for rectal cancer; however, real-world data are insufficient. This study aimed to compare the short-term outcomes and perioperative costs of laparoscopic and robotic surgery for rectal cancer using a real-world database.

Methods: The data of patients who underwent laparoscopic or robotic surgery for rectal cancer between January 2018 and January 2021 from a nationwide Japanese inpatient database provided by Medical Data Vision Co.

View Article and Find Full Text PDF

Background: The phase III NAPOLI-3 trial, which upgraded FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin) to NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil), demonstrated the superiority of NALIRIFOX over GEMNABP (gemcitabine and nab-paclitaxel) as the first-line treatment for metastatic pancreatic ductal adenocarcinoma. The purpose of this study was to assess the cost-effectiveness of NALIRIFOX, FOLFIRINOX, and GEMNABP, and to simulate the price of liposomal irinotecan at which NALIRIFOX could achieve cost-effectiveness.

Methods: A partitioned survival model was performed to evaluate the cost-effectiveness of NALIRIFOX, FOLFIRINOX and GEMNABP from the perspective of the Chinese healthcare system.

View Article and Find Full Text PDF

This study provides the first empirical evidence of the impact of leaks in natural gas distribution pipelines on nearby home prices. Using high-resolution property transaction data in Massachusetts and a difference-in-differences approach, we find that gas leaks significantly reduce nearby home prices by 2.61% ($11,700) on average.

View Article and Find Full Text PDF

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma.

Therap Adv Gastroenterol

January 2025

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao.

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality globally. Recent advancements in targeted therapies have improved outcomes for advanced HCC, yet therapeutic options remain limited. The CARES-310 trial demonstrated that camrelizumab plus rivoceranib significantly improves survival compared to sorafenib for advanced HCC.

View Article and Find Full Text PDF

Telemedicine (TM) has emerged as a valuable tool in managing pediatric type 1 diabetes (T1D), particularly during the COVID-19 pandemic when traditional in-person visits were limited. This narrative review examines the impact of TM on patient-provider relationships, glycemic control, and overall diabetes management in children and adolescents with T1D. Studies consistently demonstrate high levels of patient and provider satisfaction with TM, citing increased consultation frequency, reduced travel burdens, and lower associated costs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!